Clinical trials: HNSCC, open to volunteers
NPC, HNSCC
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
Phase II: To evaluate the safety and tolerability of IAE0972 combined with chemotherapy selected by doctors for R/M HNSCC/NPC after failure or progress of ≤2-line system therapy, and to determine the MTD of combined therapy.
- Conditions
- NPC, HNSCC, Recurrence, Metastasis
- Trial name
- NCT06719479
- Testing
- IAE0972+ Methotrexate, IAE0972+Docetaxel, IAE0972+Gemcitabine
- Volunteers
- 60 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Head and Neck Squamous Cell Carcinoma (HNSCC)
Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This prospective, single-arm, exploratory, phase II study was designed to evaluate the efficacy and safety of Trilaciclib in reducing chemotherapy-induced neutropenia in patients with recurrent or metastatic head and neck…
- Trial name
- NCT06714266
- Testing
- Trilaciclib
- Volunteers
- 30 people
- Sponsor
- Shandong Cancer Hospital and Institute
Solid Tumor, HNSCC
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors.
- Conditions
- Solid Tumor, HNSCC, RCC, CRC
- Trial name
- SPX-303 (NCT06259552)
- Testing
- SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody
- Where
- 4 sites in United States
- Volunteers
- 232 people
- Sponsor
- SparX Biotech(Jiangsu) Co., Ltd.
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma
A Randomized, Phase II Study of MRG003 in Combination With Pucotenlimab Injection ± Cisplatin in Patients With Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT06530914
- Testing
- MRG003 combined with Pucotenlimab, MRG003 combined with Pucotenlimab+Cisplatin
- Volunteers
- 30 people
- Sponsor
- Lei Liu
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC
To explore the efficiency and safety of Tislelizumab combinated with carboplatin and polymeric micellar paclitaxel as a new neoadjuvant treatment regimen for resectable HNSCC patients with clinical positive lymph node metastasis
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, HNSCC, Head Cancer Neck
- Trial name
- NCT06366945
- Testing
- Carboplatin, Tislelizumab, Polymeric Micellar Paclitaxel
- Volunteers
- 85 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HNSCC
Artificial Intelligence in Functional Imaging for Individualized Treatment of Head and Neck Squamous Cell Carcinoma Patients
The two curative treatment modalities for patients with HNSCC - primary chemoradiation (CRT) or primary surgery (often combined with postoperative (C)RT) - are both associated with serious side effects for which reason further…
- Trial name
- KIVAL-KHT (NCT05192655)
- Testing
- Observation
- Where
- Germany
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
HNSCC, Oral Cancer
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
In this study, 200 patients with resectable head and neck squamous cell carcinoma (T3 or T4, N0) were enrolled and preoperatively combined with pembrolizumab (PD-1 inhibitor), carboplatin, and albumin-binding paclitaxel.
- Conditions
- HNSCC, Oral Cancer, PD-1
- Trial name
- HNC-SYSU-002 (NCT05980702)
- Testing
- Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses, Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HNSCC, Radiotherapy
PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy
In patients with locally advanced head and neck squamous cell carcinoma undergoing standard surgical treatment after neoadjuvant immunochemotherapy, can PD-1 inhibitor therapy be used instead of adjuvant radiotherapy for both…
- Conditions
- HNSCC, Radiotherapy, PD-1
- Trial name
- HNC-SYSU-003 (NCT05980715)
- Testing
- PD-1inhibitor, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 324 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University